Approved by the FDA for managing Type 2 diabetes and chronic weight management, it may cause mild side effects such as nausea, vomiting, diarrhea, or constipation, especially when starting
Most compounding protocols cap total nightly dose at approximately 30 mcg regardless of weight until response data are reviewed
These interactions may lead to: Severe, life-threatening, and/or fatal adverse reactions due to drug interactions have been reported in patients treated with PAXLOVID
Hunger between meals increases
They are prepared by licensed compounding pharmacies under physician prescription and have not been evaluated through clinical trials for safety, efficacy, or therapeutic equivalence to any FDA-approved medications
IGF1 LR3 Research Cell Division Like IGF 1, IGF1 LR3 is a potent stimulus for cell division and proliferation